Allergan PLC (AGN)

AGN (NYSE:Drugs) EQUITY
$247.03
pos +0.71
+0.29%
Today's Range: 244.88 - 248.58 | AGN Avg Daily Volume: 4,192,000
Last Update: 02/23/17 - 4:01 PM EST
Volume: 1,953,891
YTD Performance: 17.69%
Open: $245.50
Previous Close: $246.32
52 Week Range: $184.50 - $301.32
Oustanding Shares: 374,952,199
Market Cap: 92,673,185,505
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 9
Moderate Buy 3 3 3 3
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.62 1.62 1.62 1.57
Latest Dividend: 0.70
Latest Dividend Yield: 1.13%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: -113.38
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
-113.38 6.50 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
29.31% -13.82% 13.16%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.40 0.70 0.19
Net Income 282.20 0.20 0.00
EPS 281.40 -8.20 0.00
Earnings for AGN:
EBITDA -1.08B
Revenue 14.57B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $3.43 $4.04 $16.02 $17.88
Number of Analysts 8 7 11 9
High Estimate $3.63 $4.17 $16.17 $18.48
Low Estimate $3.31 $3.85 $15.90 $17.30
Prior Year $3.04 $3.35 $13.51 $16.02
Growth Rate (Year over Year) 12.75% 20.55% 18.57% 11.60%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Doug Kass

 | Feb 23, 2017 | 8:33 AM EST
Allergan (AGN) expresses no interest in acquiring Valeant (VRX) . …
RMPIA
By

Doug Kass

 | Feb 22, 2017 | 5:07 PM EST
"Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria." -- Sir John Templeton 
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 11:45 AM EST
Icahn may have a tough time finding interest in this behemoth.
RMPIA
By

Bret Jensen

 | Feb 22, 2017 | 10:00 AM EST
These two large-cap drug giants should be core parts of any well-diversified portfolio.
RMPIA
By

Doug Kass

 | Feb 16, 2017 | 6:00 PM EST
While I was away this afternoon, the market bent a bit but didn't break. 
RMPIA
By

Doug Kass

 | Feb 16, 2017 | 8:23 AM EST
I am upgrading my Allergan price target from $260 to $310 AGN remains my favorite large-cap long for 2017 
RMPIA
By

Bret Jensen

 | Feb 15, 2017 | 11:30 AM EST
M&A activity is in a serious upswing, and here are some names to watch.
RMPIA
By

Doug Kass

 | Feb 13, 2017 | 3:08 PM EST
 
RMPIA
By

Doug Kass

 | Feb 13, 2017 | 10:06 AM EST
Based on the Allergan (AGN) conference call (more on this tomorrow!), I am raising my year-end 2017 price target once again.   …
RMPIA
By

Jim Cramer

 | Feb 10, 2017 | 2:30 PM EST
Amazon, J&J, IBM and others don't deserve this treatment.
The SPDR S&P Biotech ETF (XBI) was trading in a four month symmetrical triangle b...
Join me later today as I bring back Toni Hanser to a webinar.  Toni has been away for...
Here is a well defined zone to look for buy triggers against...defining the risk below it!...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 1...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.